Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, and Maternal-Fetal Medicine, Tufts Medical Center, Boston, MA 02111, USA.
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4448-53. doi: 10.1073/pnas.1000803107. Epub 2010 Feb 16.
The peptide substance P (SP) has been implicated in inflammatory conditions, such as psoriasis, where mast cells and VEGF are increased. A relationship between SP and VEGF has not been well studied, nor has any interaction with the proinflammatory cytokines, especially IL-33. Here we report that SP (0.1-10 microM) induces gene expression and secretion of VEGF from human LAD2 mast cells and human umbilical core blood-derived cultured mast cells (hCBMCs). This effect is significantly increased by coadministration of IL-33 (5-100 ng/mL) in both cell types. The effect of SP on VEGF release is inhibited by treatment with the NK-1 receptor antagonist 733,060. SP rapidly increases cytosolic calcium, and so does IL-33 to a smaller extent; the addition of IL-33 augments the calcium increase. SP-induced VEGF production involves calcium-dependent PKC isoforms, as well as the ERK and JNK MAPKs. Gene expression of IL-33 and histidine decarboxylase (HDC), an indicator of mast cell presence/activation, is significantly increased in affected and unaffected (at least 15 cm away from the lesion) psoriatic skin, as compared with normal control skin. Immunohistochemistry indicates that IL-33 is associated with endothelial cells in both the unaffected and affected sites, but is stronger and also associated with immune cells in the affected site. These results imply that functional interactions among SP, IL-33, and mast cells leading to VEGF release contribute to inflammatory conditions, such as the psoriasis, a nonallergic hyperproliferative skin inflammatory disorder with a neurogenic component.
肽物质 P(SP)已被牵连到炎症条件,如牛皮癣,其中肥大细胞和 VEGF 增加。SP 与 VEGF 之间的关系尚未得到很好的研究,也没有与促炎细胞因子,特别是 IL-33 的任何相互作用。在这里,我们报告 SP(0.1-10 μM)诱导人 LAD2 肥大细胞和人脐血源性培养肥大细胞(hCBMC)中 VEGF 的基因表达和分泌。在这两种细胞类型中,IL-33(5-100ng/mL)的共给药显著增加了这种效应。SP 对 VEGF 释放的影响被 NK-1 受体拮抗剂 733,060 抑制。SP 迅速增加细胞质钙,而 IL-33 则以较小的程度增加;添加 IL-33 会增强钙的增加。SP 诱导的 VEGF 产生涉及钙依赖性 PKC 同工型,以及 ERK 和 JNK MAPK。与正常对照皮肤相比,受影响和未受影响(至少距病变 15cm 远)的牛皮癣皮肤中,IL-33 和组氨酸脱羧酶(HDC)的基因表达明显增加,HDC 是肥大细胞存在/激活的指标。免疫组织化学表明,IL-33 与未受影响和受影响部位的内皮细胞有关,但在受影响部位更强,并且还与免疫细胞有关。这些结果表明,SP、IL-33 和肥大细胞之间的功能相互作用导致 VEGF 释放,导致炎症条件,如牛皮癣,一种非过敏性过度增殖性皮肤炎症性疾病,具有神经源性成分。